1. Introduction {#sec1}
===============

At present, various imaging modalities play an important role in diagnosis, staging, follow-up, and therapeutic evaluation of patients with cancer. Positron emission tomography/computed tomography with F-18 based fluorodeoxyglucose (^18^F-FDG PET/CT) is considered as an accurate method for characterizing tumor lesions due to the availability of anatomic and glucose metabolic information of tumor \[[@B1]\]. The standardized uptake value (SUV) is the most frequently used parameter derived from ^18^F-FDG PET, which has been used for assessing tumor aggressiveness, differentiating benign from malignant tumors, and monitoring treatment \[[@B2], [@B3]\].

Magnetic resonance imaging (MRI) is another important tool to detect and characterize tumors. Specifically, diffusion-weighted imaging (DWI) provides an additional promising dimension to the conventional anatomical MRI. Apparent diffusion coefficient (ADC) is a parameter obtained by MR-DWI, reflecting the Brownian movement of water molecules. The ADC value has been shown to link with the cell density, microvascular circulation, and membrane integrity of a tumor tissue \[[@B4]\].

Although glucose metabolism and cell density represent two different facets of tumor biology, many researchers tried to find the relationship between ADC and SUV. However, there is a controversy in this relationship. Some data demonstrated that there was no significant correlation observed between SUV and ADC \[[@B5]\], while other studies reported that SUV was inversely correlated with ADC \[[@B6], [@B7]\]. Given the conflicting evidence on this issue, we conducted this meta-analysis to explore the correlation between ADC and SUV in cancer patients.

2. Methods {#sec2}
==========

2.1. Literature Search {#sec2.1}
----------------------

Two observers independently searched the PubMed (MEDLINE included), EMBASE, and Cochrane Library databases for published studies. The search was limited to publications written in English. The databases were searched using the terms ((positron emission tomography) OR (PET) OR (positron emission tomography/computed tomography) OR (PET/CT) OR (PET-CT) OR (positron emission tomography-computed tomography)) AND ((18F-FDG) OR (fluorodeoxyglucose) OR (FDG) OR (18FDG) OR (FDG-F18)) AND ((apparent diffusion coefficient) OR (ADC)) AND ((Diffusion Magnetic Resonance Imaging) OR (Diffusion MRI) OR (Diffusion Weighted MRI) OR (DWI) OR (diffusion-weighted magnetic resonance imaging) OR (MRI DWI) OR (diffusion-weighted imaging) OR (diffusion-weighted MRI)).

2.2. Study Identification and Selection {#sec2.2}
---------------------------------------

Two independent reviewers evaluated the potentially relevant articles on the basis of the inclusion and exclusion criteria. Articles were included if they met the following criteria:Investigation of the relationship between ADC measured by MR and SUV measured with PET or PET/CT scanningStudies focusing on patients with malignant tumors, which may include patients with benign conditions as long as the vast majority of patients (\>50%) in the study had cancerResearch article published in the peer-reviewed journals

The exclusion criteria included the following:Data or part of data presented in more than one article (in this case, the article containing the latest and/or the most complete data was chosen)Animal studies, reviews, case report, letters, editorials, abstracts, comments, and in vitro studiesStudies including less than 10 patients or 10 lesionsArticles without sufficient information for calculation of correlation coefficientIf there was discordance among the 2 independent researchers for one study, its eligibility was decided by the 3rd investigator.

2.3. Data Extraction {#sec2.3}
--------------------

The data were extracted from the included literatures by two investigators (Shengming Deng and Bin Zhang) independently, and the extracted contents included the following:Overall characteristics of studies, including authors, year of publication, number of patients and lesions, and tumor typeTechnical characteristics of PET or PET/CT measurement of ^18^F-FDG, including characteristics of the scanner, ^18^F-FDG dose, uptake time of the tracer, emission scan time, delineation of the tumor, and indexes of uptake (SUV~max~, SUV~mean~, or others)Technical characteristics of MR or PET/MR measurement ADC covered imaging equipment, *b* value, MRI field strength, and the index used to characterize the ADC (average, minimum, or others)The degree of correlation between ADC and SUV, including Spearman\'s correlation coefficient (SCC), Pearson\'s correlation coefficient (PCS), and*r*^2^. If the article did not report the value of correlation coefficient *r* directly, *r* value was calculated based on the raw data or scatter plot using the free software Engauge Digitizer (free software downloaded from <https://sourceforge.net>) and the SPSS 18.0 software. SCC was used for this meta-analysis. Since the SCC has already been processed by logarithmic conversion, it does not need to undergo the conversion again. The published PCSs were converted to SCCs for further analysis \[[@B8]\]. The sampling of SCC is not normally distributed. Because its confidence interval (CI) depends on the value of correlation coefficient, we converted the SCC by Fisher transformation to obtain *z* value with an approximately normal distribution. *z* value was then converted by inverse Fisher transformation to obtain the SCC and the corresponding CI.If more than one correlation coefficient value calculated according to various SUV indexes or ADC indexes was reported in the article, the lowest value was chosen.

When disagreements occurred between the two reviewers, a third investigator joined to vote for a decision.

2.4. Methodology of Quality Assessment {#sec2.4}
--------------------------------------

Two investigators (Shengming Deng and Bin Zhang) assessed the quality of the articles independently according to the QUADAS-2 \[[@B9]\], which consists of 2 parts of contents: "risk assessment" and "practical application." The former was assessed from 4 key domains as patient selection, index test, reference standard, and flow and timing, and the latter included 3 aspects as patient selection, index test, and reference standard.

To make sure that the QUADAS-2 tool is applicable to the present study, we designated SUV measurement as the "reference test" and ADC measurement as the "index test." In this study, we chose one month as the threshold interval between PET or PET/CT examination and DWI-MRI detection in case tumor biology will change much. A third reviewer was introduced when there were assessing differences between the two observers.

2.5. Meta-Analysis {#sec2.5}
------------------

The pooled correlation coefficient between SUV and ADC was calculated according to the values of correlation coefficients obtained in each individual study. Correlation coefficient values were converted by Fisher\'s *r*-to-*z* transformation to obtain approximately normally distributed *z* values to further calculate 95% CIs. The random-effects model was used for the pooled analysis in this study. Correlations were classified as poor (correlation coefficient *r* \< 0.20), average (*r* = 0.20--0.39), moderate (*r* = 0.40--0.59), significant (*r* = 0.60--0.79), and strong (*r* \> 0.80) \[[@B10]\]. Publication bias was assessed by means of Begg\'s funnel plots and Begg\'s statistical test.

The heterogeneity of *r* values between studies was tested by calculating *Q* statistic and the inconsistency index (*I*^2^). *p* \< 0.05 or*I*^2^ \> 50% indicated the presence of heterogeneity. In case of the existence of heterogeneity, a sensitivity analysis was performed for all studies to further investigate the study heterogeneity. In a subgroup analysis, studies were stratified according to tumor type and correlation coefficient value (SUV~mean~/ADC~mean~, SUV~max~/ADC~min~, SUV~max~/ADC~mean~, etc.).

Statistical analysis was performed using STATA 11 software package (Stata Corporation, College Station, TX, USA). *p* \< 0.05 was considered statistically significant.

3. Results {#sec3}
==========

3.1. Literature Search and Selection of Studies {#sec3.1}
-----------------------------------------------

The original search identified 145 articles in PubMed and 759 articles in EMBASE. After removing duplicates, 789 abstracts were screened according to the evaluation criteria, and 115 in total were selected to be read in full as potentially eligible. After reading the full texts, 66 studies were excluded for the following reasons: (1) the article did not involve the evaluation of the relationship between ADC value and ^18^F-FDG uptake (*n* = 38); (2) the number of cases or tumor sites studied was fewer than 10 (*n* = 13); (3) the raw data in the article failed to generate the correlation coefficient values (*n* = 10); (4) part of the data in the study appeared in other articles (*n* = 3); (5) parameters measured by two individual reviewers were presented in the article which was difficult to choose (*n* = 1); and (6) most of the cases studied were benign tumors (*n* = 1). [Figure 1](#fig1){ref-type="fig"} describes the study selection process and results according to the PRISMA guidelines. Finally, 49 published articles were included in the present study \[[@B11]--[@B59]\].

3.2. Study Characteristics {#sec3.2}
--------------------------

The selected studies were published between 2008 and 2015. The median number of patients per study was 32 (range: 7--131) with a total number of 1927 patients. In some studies, more than one tumor site was analyzed on several patients; therefore, a total of 2356 samples were assessed in the meta-analysis. Studies covering a range of cancer sites are summarized in [Table 1](#tab1){ref-type="table"}.

The most studied tumor location was the lung with 10 studies. The second tumor type was head and neck cancer, for which there were 6 studies. Five groups studied breast cancer, lymphoma, and cervical cancer. Other tumor types include metastatic gastrointestinal stromal tumors (GIST), brain cancer, hepatocellular cancer, esophageal cancer, peritoneal carcinomatosis, pancreatic cancer, and gastric, rectal, uterus, hepatocellular, and various types.

For MR-DWI examination, forty-one studies used a stand-alone MR scanner, while 8 studies used a PET/MR scanner. For MRI field strength, twenty-four studies used 1.5 T, twenty-three studies used 3.0 T, and 2 studies used both. For the index of ADC, twenty-six studies used ADC~mean~, fifteen studies used ADC~min~, and 8 studies used other indexes. For ^18^F-FDG PET scan, SUV~max~, SUV~mean~, and other SUV were used to calculate *r* values in 29, 11, and 9 studies, respectively ([Table 2](#tab2){ref-type="table"}).

3.3. The Results of QUADAS-2 Assessing the Quality of the Included Articles {#sec3.3}
---------------------------------------------------------------------------

As shown in [Figure 2](#fig2){ref-type="fig"}, the results of QUADAS-2 assessing the quality of the included articles indicated that the results of 10 studies adequately addressed all risk of bias domains. Among all the 49 studies, risk of bias was high or unclear with regard to patient selection for 7 studies, the index text for 32 studies, the reference standard for 31 studies, and flow and timing for 14 studies.

Interpretation of ADC or SUV in a blinded fashion was an item which most studies did not report. Seventeen studies clearly stated that the index test was assessed without knowledge of the results of the reference standard, while this was unclear in 32 studies. Similarly, in 18 studies, the interpretation of reference standard was clearly stated as under unknown index test, while the other 31 studies did not state the interpretation of reference standard clearly.

Acceptable delay between reference and index tests was the item which many studies did not report. Eleven studies provided no information about the time interval between the execution of MR-DWI and the ^18^F-FDG PET/CT scan. In 3 studies documented, the interval was more than 4 weeks.

In addition, patients enrolled in 1 study were investigated on residual tumors after completion of therapy. In these patients, whether the relationship between ^18^F-FDG uptake and ADC value differs from that in patients with pretherapeutic tumor is unclear; therefore, the risk of case selection bias in this study was considered unclear in the present analysis.

3.4. The Results of a Meta-Analysis {#sec3.4}
-----------------------------------

The data provided by the finally chosen studies all met the standard of meta-analysis. *r* values for 3 studies were calculated from provided *r*^2^, and *r* values for 2 other studies were determined from the provided scatter plot. For 3 other studies, *r* values were calculated based on the provided raw data of corresponding ADC and SUV.

Final combined *r* value calculated from all the included articles was −0.35 (95% CI: −0.42--−0.28), but the results of heterogeneity test indicated the presence of marked heterogeneity among studies (*I*^2^ = 78.4%; *p* \< 0.01; [Figure 3](#fig3){ref-type="fig"}). We then conducted a sensitivity analysis by excluding each article at a time to observe its effect on the final outcome, but the results showed that no individual study contributed more greatly to the total heterogeneity. The results of Begg\'s test indicated no significant publication deviation among the included articles (*p* \> 0.05; [Figure 4](#fig4){ref-type="fig"}).

As shown in [Figure 5](#fig5){ref-type="fig"}, the subgroup analysis for tumor types showed that combined *r* for the 10 studies of lung cancer was −0.35 (95% CI: −0.49--−0.20), and there was significant heterogeneity among the included studies (*I*^2^ = 68.6%; *p* \< 0.01). Combined *r* value for the 6 studies on head and neck cancer was −0.31 (95% CI: −0.44--−0.19;*I*^2^ = 11.0%; *p* \> 0.05) which displayed no heterogeneity. Combined *r* value for the subgroup of 5 studies on lymphoma and cervical cancer was −0.12 (95% CI: −0.34--0.11) and −0.48 (95% CI: −0.59--−0.37), respectively, without significant heterogeneity ((*I*^2^ = 51.6%; *p* \> 0.05) and (*I*^2^ = 0.0%; *p* \> 0.05)). Combined *r* value for the 5 studies on breast cancer was −0.24 (95% CI: −0.41--−0.08;*I*^2^ = 68.2%; *p* \< 0.01).

Results for the subgroup analysis based on correlation coefficient value are shown in [Figure 6](#fig6){ref-type="fig"}. Eight studies in SUV~mean~/ADC~mean~ resulted in *r* = −0.39 (95% CI: −0.54--−0.23), with*I*^2^ = 62.7% (*p* \< 0.01). Pooled *r* for ten studies in SUV~max~/ADC~min~ was −0.47 (95% CI: −0.59--−0.34), with*I*^2^ = 70.3% (*p* \< 0.01). In SUV~max~/ADC~mean~, sixteen studies provided *r* = −0.29 (95% CI: −0.43--−0.14) with*I*^2^ = 80.5% (*p* \< 0.01).

4. Discussion {#sec4}
=============

In the recent years, the correlation between ADC and SUV has been increasingly studied. In the present study, we investigated the relationship between ^18^F-FDG uptake and ADC value using meta-analysis methods. Our meta-analysis showed that, in cancer patients, there was an average negative correlation between the SUV and ADC. Subgroup analysis on different tumor types indicated that degrees of correlation among different tumor types varied and heterogeneity of some subgroups changed significantly. The subgroup analysis on various correlation coefficient values indicated that combined *r* values of subgroups did not show significant changes, and there were no significant changes in heterogeneity.

In this study, we used QUADAS-2 as an evidence-based quality assessment tool. In the present analysis, the vast majority of the articles did not mention whether the test results of DWI-MRI and ^18^F-FDG PET (or PET/CT) are interpreted blindly. In most studies, the time interval between ^18^F-FDG PET (or PET/CT) imaging and the acquirement of ADC was not clearly stated. In addition, some studies did not address the inclusion criteria of patients adequately. The above problems may increase the bias of study.

DWI provides an excellent tissue contrast through detection of differences in the Brownian motion of water molecules in tissues. ADC is a parameter calculated from DWI and altered by any architectural changes in the proportion of extracellular to intracellular water molecules because the diffusion of water molecules is disturbed by intracellular organelles and macromolecules \[[@B60]\]. Malignant tumors usually show decreased ADC values because they are characterized by increased cellularity, larger nuclear/cytoplasmic ratio, and less extracellular space relative to normal tissues which restrict the diffusion of water molecules \[[@B61]\]. Currently, ^18^F-FDG PET/CT has been considered as the standard of care in various cancers. ^18^F-FDG uptake is correlated with the number of viable tumor cells and their metabolic activity. Glucose utilization in tumors is increased due to the Warburg effect \[[@B62]\]. Recently, the introduction of simultaneous PET/MRI makes it possible to combine functional and metabolic studies in malignancies in one examination. It was postulated that there is a correlation between ADC and SUV. The present study showed that the pooled correlation coefficient between SUV and ADC was −0.35, indicating an average negative correlation. A possible explanation of this result might be that although there is a certain overlap of the information provided by ^18^F-FDG PET and DW-MRI, the two parameters (SUV and ADC) reflect different tumor biology. For example, except for cellularity, ADC is correlated directly with tumor necrosis because of increased presence of free water in the necrotic area \[[@B63]\]. However, ^18^F-FDG PET demonstrates tumor necrosis as photopenic defects. In addition, although the ADC measurement is derived from DWI which is an MR sequence that is known for a high detection rate of lesions, it is not always very specific \[[@B64]\]. Our result suggested that ^18^F-FDG PET and DWI-MRI might complement each other on the clinical diagnosis.

We conducted a subgroup analysis based on different tumor types. The meta-analysis about ADC and tumor cellularity correlation revealed no notable variation between the subgroups based on cancer type \[[@B65]\]. In this study, our results showed that the correlation between ^18^F-FDG SUV and ADC differed between histological types. Combined correlation coefficients range from −0.12 (lymphoma, *n* = 5) to −0.59 (pancreatic cancer, *n* = 2). Correlation was moderate in brain, cervix, and pancreas, average in lung, head and neck, breast, and rectum, and poor in lymphoma. However, this issue needs to be further explored with more experiments.

The present study has some potential limitations. First, although the number of patients included in this study was large, they were relatively limited to a certain type of tumors. This may cause limitations in our inference based on the results of subgroup analysis on different histological types. Second, our meta-analysis was based only on published studies which provided *r* values or raw data which can be used to calculate *r* values. Other articles which only report positive or negative results without specific data were excluded from this analysis. In addition, this study was restricted to articles published in English, which would cause publication bias. However, the results of Begg\'s test showed no evidence of publication bias. We also used the random-effects model to reduce heterogeneity. Therefore, the results of the present study are reliable.

In short, although there are limitations in this study, our meta-analysis demonstrated an average negative correlation between the SUV and ADC values in patients with cancer. Sufficient data support a moderate correlation for brain, cervix, and pancreas, average correction for lung, head and neck, breast, and rectum, and poor for lymphoma. However, a prospective study with a larger population is warranted to validate these findings in different cancer types.
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###### 

^18^F-FDG PET scan characteristics and MRI scanner.

  Author                                 Year   Scanner                                                                                                                                     FDG dose (MBq)   Uptake period (min)   Emission time (min)   SUV index            Delineation
  -------------------------------------- ------ ------------------------------------------------------------------------------------------------------------------------------------------- ---------------- --------------------- --------------------- -------------------- ---------------------
  Mori et al. \[[@B11]\]                 2008   GE Discovery ST PET/CT + Philips Intera Achieva Nova Dual 1.5 T MR                                                                          3.7/kg           60                    3                     SUV-CR               Manual
  Ho et al. \[[@B12]\]                   2009   GE Discovery ST16 PET/CT + Siemens Tim Trio 3.0 T MR                                                                                        333--407         50                    3                     SUV~max~/SUV~mean~   Automatic
  Palumbo et al. \[[@B13]\]              2009   GE Advance PET + GE 1.5 T MR                                                                                                                444--555         45                    6--10                 SUV-CR               Semiautomatic
  Aoyagi et al. \[[@B14]\]               2010   PET + Philips Intera Achieva Nova Dual 1.5 T MR                                                                                             N                N                     N                     SUV~max~             N
  Nakajo et al. \[[@B15]\]               2010   GE Discovery STE PET/CT + Philips Intera Achieva 1.5 T MR                                                                                   3.7/kg           60                    2.5                   SUV~max~             Automatic
  Punwani et al. \[[@B16]\]              2010   GE Discovery LS PET/CT + Siemens Avanto 1.5 T MR                                                                                            370              60                    N                     SUV~max~             Manual
  Tanimoto et al. \[[@B17]\]             2010   Toshiba Aquiduo PET/CT + GE Signa HDx 3.0 T MR                                                                                              217.8--372.5     60                    3                     SUV                  Automatic
  Choi et al. \[[@B18]\]                 2011   Philips Gemini or Siemens Biograph 40 PET/CT + GE Signa HDx or HDxt 1.5 T MR                                                                5.2/kg           60                    2                     SUV~mean~            Manual
  Fruehwald-Pallamar et al. \[[@B19]\]   2011   Siemens Biograph 64 PET/CT + Philips Achieva 3.0 T MR                                                                                       300              50                    3                     SUV~max~             Automatic
  Gu et al. \[[@B20]\]                   2011   GE Discovery VCT PET/CT + Philips Achieva 3.0 T MR                                                                                          4.8/kg           60                    4                     SUV~max~             Automatic
  Ohba et al. \[[@B21]\]                 2011   GE Discovery ST PET/CT + Philips Achieva 3.0 T or Philips Gyroscan Intera Achieva Nova Dual 1.5 T MR                                        3.7/kg           60                    3                     SUV-CR               N
  Usuda et al. \[[@B22]\]                2011   Siemens Biography Sensation 16 PET/CT + Siemens Magnetom Avanto 1.5 T MR                                                                    185              60                    3                     SUV~max~             Automatic
  Wu et al. \[[@B23]\]                   2011   GE Discovery STE 16 PET/CT + Siemens Trio-Tim 3.0 T MR                                                                                      370              60                    3                     SUV~max~             Manual
  Cafagna et al. \[[@B24]\]              2012   GE Discovery STE 16 PET/CT + Philips Achieva 1.5 T MR                                                                                       3.7/kg           60                    3                     SUV~max~             N
  Choi et al. \[[@B25]\]                 2012   Siemens Biograph Duo or Biograph Truepoint PET/CT + Philips Achieva 1.5 T or Siemens Magnetom Verio 3.0 T MR                                N                N                     2-3                   SUV~max~             N
  Matsushima et al. \[[@B26]\]           2012   Toshiba Aquiduo PCA-7000B PET/CT + GE Signa Excite HDxt 1.5 T MR                                                                            3.7/kg           60                    6                     SUV-CR               Manual
  Nakajo et al. \[[@B27]\]               2012   GE Discovery STE PET/CT + Siemens Magnetom Avanto 1.5 T MR                                                                                  3.7/kg           60                    N                     SUV~max~             Automatic
  Nakamatsu et al. \[[@B28]\]            2012   Toshiba Aquiduo 16 PET/CT + Siemens Magnetom Symphony 1.5 T MR                                                                              166.7--320.8     60                    2                     SUV~mean~            Manual
  Nakamura et al. \[[@B29]\]             2012   Siemens Biograph LS/Sensation 16 PET/CT + Siemens Magnetom Avanto 1.5 T MR                                                                  3.7/kg           90                    2.4                   SUV~max~             Manual
  Regier et al. \[[@B30]\]               2012   Philips Gemini GXL 10 PET/CT + Philips Achieva 1.5 T MR                                                                                     5/kg             60                    1--1.5                SUV~max~             N
  Ahn et al. \[[@B31]\]                  2013   Siemens Biograph Truepoint 40 PET/CT + Siemens Magnetom Tim Trio 3.0 T MR                                                                   5.5/kg           45                    N                     SUV~max~             N
  Byun et al. \[[@B32]\]                 2013   Siemens Biograph 6 PET/CT + Siemens Magnetom TrioA Tim 3.0 T MR                                                                             7.4/kg           60                    3.5                   SUV~max~             Automatic or manual
  Gong et al. \[[@B33]\]                 2013   GE Discovery VCT PET/CT + Philips Achieva 3.0 T MR                                                                                          4.8/kg           60                    4                     SUV~max~             Manual
  Nakamura et al. \[[@B34]\]             2013   Siemens Biograph LS/Sensation 16 PET/CT + Siemens Magnetom Avanto 1.5 T MR                                                                  3.7/kg           90                    2.4                   SUV~max~             Manual
  Rakheja et al. \[[@B35]\]              2013   Siemens Biograph mCT PET/CT + Siemens Biograph mMR PET/MR                                                                                   555              45                    2                     SUV~max~             Manual
  Schmidt et al. \[[@B36]\]              2013   Siemens HI-REZ Biograph 16 or Siemens Biograph mCT PET/CT + Siemens Biograph mMR PET/MR                                                     317--381         55--61                2-3                   SUV~max~             N
  Tsuchida et al. \[[@B37]\]             2013   GE Discovery LS4 PET/CT + GE Signa Excite 1.5 T MR                                                                                          185              50                    2                     SUV~mean~            N
  Varoquaux et al. \[[@B38]\]            2013   Siemens Biograph 16-slice PET/CT + Siemens Espree 1.5 T or Trio 3.0 T MR                                                                    370              60                    3                     SUV                  Manual
  Baba et al. \[[@B39]\]                 2014   GE Advance NXi PET/CT + Philips Intera Achieva 1.5 T MR                                                                                     3.7/kg           60                    2                     SUV~max~             Manual
  de Jong et al. \[[@B40]\]              2014   Siemens Biograph 40 True Point or Philips Gemini TOF PET/CT + Philips Achieva or Siemens Magnetom Avanto 1.5 T MR                           2.0--3.7/kg      60--75                2-3                   SUV~max~             Manual
  Er et al. \[[@B41]\]                   2014   GE Discovery ST PET/CT + Siemens Magnetom Verio 3.0 T MR                                                                                    5.55/kg          50--60                N                     SUV~max~             Manual
  Giganti et al. \[[@B42]\]              2014   GE Discovery ST, Discovery STE, Discovery-690, or Philips Gemini GXL PET/CT + Philips Achieva 1.5 T MR                                      3.7/kg           60                    2.5                   PVC-SUV~mean~        Automatic
  Grueneisen et al. \[[@B43]\]           2014   Siemens Biograph mMR PET/MR                                                                                                                 201 ± 69         102 ± 39              8                     SUV~max~             Manual
  Iizuka et al. \[[@B44]\]               2014   GE Discovery ST Elite PET/CT + Siemens Avanto 1.5 T MR                                                                                      3.7/kg           60                    2-3                   SUV~max~             N
  Sakane et al. \[[@B45]\]               2015   Philips Gemini GXL PET/CT + GE Signa HDxt 3.0 T MR                                                                                          3.7/kg           60                    2                     SUV~mean~            Manual
  Schwenzer et al. \[[@B46]\]            2014   PET/CT + Siemens Biograph mMR PET/MR                                                                                                        294--386         62 ± 4                6                     SUV~mean~            Manual
  Sun et al. \[[@B47]\]                  2014   Philips Ingenuity TF PET/MR                                                                                                                 240--350         60 ± 12               4                     SUV~mean~            Automatic
  Yu et al. \[[@B48]\]                   2014   GE Discovery VCT PET/CT + Philips Achieva 3.0 T MR                                                                                          4.8/kg           60                    2.5                   SUV~mean~            Manual
  Zhang et al. \[[@B49]\]                2014   Siemens Biograph 40 PET/CT + Siemens Trio-Tim 3.0 T MR                                                                                      5.55/kg          60                    N                     SUV~max~             N
  Zukotynski et al. \[[@B50]\]           2014   GE Advance NXi, Discovery LS, and Discovery STE; Philips G-PET; Siemens HR1 and HI-REZ Bioscan PET + 1.5 T MR                               5.55/kg          40--60                10                    SUV~mean~/WM         Manual
  Brandmaier et al. \[[@B51]\]           2015   Siemens Biograph mMR 3.0 T PET/MR                                                                                                           309 ± 70.32      130                   5                     SUV~max~             Manual
  Covello et al. \[[@B52]\]              2015   Philips Gemini TF PET/CT + Siemens Biograph mMR 3.0 T MR                                                                                    406 ± 40         81 ± 15               3                     SUV                  Automatic
  Han et al. \[[@B53]\]                  2015   GE Discovery STE PET/CT + GE Signa HDxt 1.5 T MR                                                                                            5/kg             60                    2.5                   SUV~mean~            Manual
  Heacock et al. \[[@B54]\]              2015   Siemens Biograph mCT PET/CT + Siemens Biograph mMR 3.0 T PET/MR                                                                             506.9--566.1     45                    2-3                   SUV~max~             Manual
  Karan et al. \[[@B55]\]                2016   GE Discovery STE 8 PET/CT + Siemens Avanto 1.5 T MR                                                                                         296--370         60                    2.5                   SUV~max~             Automatic
  Littooij et al. \[[@B56]\]             2015   Siemens Biograph 16 or Biograph 40 Truepoint, Philips Gemini TOF or Allegro PET-CT + Philips Achieva, Siemens Avanto or GE Signa 1.5 T MR   2--3.7/kg        60                    N                     SUV~max~             N
  Liu et al. \[[@B57]\]                  2015   Siemens Biograph 40 PET/CT + GE Signa HDE 1.5 T MR                                                                                          5.55/kg          60                    N                     SUV~max~             N
  Metz et al. \[[@B58]\]                 2015   Siemens Biograph Sensation 16 PET/CT + Siemens Magnetom Avanto 1.5 T MR                                                                     456 ± 25         64 ± 3                2                     SUV~mean~            Manual
  Schaarschmidt et al. \[[@B59]\]        2015   Siemens mCT™ PET/CT + Siemens Biograph mMR PET/MR                                                                                           280 ± 50         58 ± 11               2                     SUV~mean~            Manual

N: not reported.

###### 

MRI characteristics, cancer types, and *r* values.

  Author                                 Year   Nation        Number of patients   Number of tumors   Tumor                                                Age                  Design          Field           Index                *b* value (s/m^2^)      *r*
  -------------------------------------- ------ ------------- -------------------- ------------------ ---------------------------------------------------- -------------------- --------------- --------------- -------------------- ----------------------- --------
  Mori et al. \[[@B11]\]                 2008   Japan         104                  140                Lung (various)                                       Adult                Prospective     1.5 T           ADC~min~             1000                    −0.504
  Ho et al. \[[@B12]\]                   2009   Taiwan        33                   33                 Cervix (various)                                     Adult                Prospective     3.0 T           ADC~min~/ADC~mean~   0 and 1000              −0.526
  Palumbo et al. \[[@B13]\]              2009   USA           15                   18                 Brain (metastases)                                   Adult                N               1.5 T           ADC-CR               N                       −0.524
  Aoyagi et al. \[[@B14]\]               2010   Japan         123                  123                Esophageal (SCC)                                     Adult                N               1.5 T           ADC                  0 and 1000              −0.398
  Nakajo et al. \[[@B15]\]               2010   Japan         44                   44                 Breast (ductal carcinoma)                            Adult                Retrospective   1.5 T           ADC~mean~            0 and 1000              −0.486
  Punwani et al. \[[@B16]\]              2010   UK            16                   53                 Lymphoma (MCL)                                       Children             N               1.5 T           ADC~mean~            500                     −0.38
  Tanimoto et al. \[[@B17]\]             2010   Japan         16                   16                 Pancreas (various)                                   Adult                N               3.0 T           ADC                  400, 800, and 1200      −0.48
  Choi et al. \[[@B18]\]                 2011   Korea         47                   47                 Head and neck (SCC)                                  Adult                Retrospective   1.5 T           ADC~mean~            1000                    −0.222
  Fruehwald-Pallamar et al. \[[@B19]\]   2011   Austria       31                   31                 Head and neck (SCC)                                  Adult                Prospective     3.0 T           ADC~mean~            0 and 800               −0.238
  Gu et al. \[[@B20]\]                   2011   China         33                   33                 Rectum (adenocarcinoma)                              Adult                N               3.0 T           ADC~min~             0 and 1000              −0.45
  Ohba et al. \[[@B21]\]                 2011   Japan         58                   76                 Lung (various)                                       N                    Prospective     1.5 T           ADC~min~             1000                    −0.31
  Usuda et al. \[[@B22]\]                2011   Japan         63                   63                 Lung (various)                                       Adult                N               1.5 T           ADC~mean~            0 and 800               −0.286
  Wu et al. \[[@B23]\]                   2011   Finland       15                   15                 Lymphoma (DLBCL)                                     Adult                Prospective     3.0 T           ADC~mean~            0 and 800               0.215
  Cafagna et al. \[[@B24]\]              2012   Italy         38                   88                 Various                                              N                    Retrospective   1.5 T           ADC                  500 and 1000            0.238
  Choi et al. \[[@B25]\]                 2012   Korea         118                  118                Breast (IDC)                                         Adult                N               1.5 and 3.0 T   ADC~mean~            0, 750, and 1000        −0.025
  Matsushima et al. \[[@B26]\]           2012   Japan         36                   36                 Glioma and lymphoma                                  Children and adult   Retrospective   1.5 T           ADC~min~             1000                    −0.68
  Nakajo et al. \[[@B27]\]               2012   Japan         26                   26                 Head and neck (SCC)                                  Adult                Retrospective   1.5 T           ADC~mean~            0 and 800               −0.566
  Nakamatsu et al. \[[@B28]\]            2012   Japan         24                   41                 Metastatic neck lymph nodes of head and neck (SCC)   Adult                Retrospective   1.5 T           ADC~min~             0 and 1000              −0.489
  Nakamura et al. \[[@B29]\]             2012   Japan         66                   66                 Cervix (various)                                     Adult                N               1.5 T           ADC~min~             0, 50, and 1000         −0.529
  Regier et al. \[[@B30]\]               2012   Germany       41                   41                 Lung (NSCLC)                                         N                    Prospective     1.5 T           ADC~min~             0 and 500               −0.46
  Ahn et al. \[[@B31]\]                  2013   Korea         21                   21                 Liver (HCC)                                          Adult                Retrospective   3.0 T           ADC~max~             50, 400, and 800        0.369
  Byun et al. \[[@B32]\]                 2013   Korea         75                   75                 Breast (IDC)                                         Adult                Retrospective   3.0 T           ADC~min~             0 and 800               −0.267
  Gong et al. \[[@B33]\]                 2013   China         7                    21                 Metastatic GIST                                      Adult                Retrospective   3.0 T           ADC~mean~            0, 150, and 1000        −0.843
  Nakamura et al. \[[@B34]\]             2013   Japan         131                  131                Endometria                                           Adult                Prospective     1.5 T           ADC~min~             0, 50, and 1000         −0.677
  Rakheja et al. \[[@B35]\]              2013   USA           24                   69                 Various                                              Adult                N               3.0 T           ADC~min~             0, 350, and 750         −0.29
  Schmidt et al. \[[@B36]\]              2013   Germany       14                   14                 Lung (various)                                       Adult                N               3.0 T           ADC~min~             0 and 800               −0.8
  Tsuchida et al. \[[@B37]\]             2013   Japan         28                   28                 Lung (various)                                       Adult                N               1.5 T           ADC                  0 and 800               0.043
  Varoquaux et al. \[[@B38]\]            2013   Switzerland   33                   34                 Head and neck (SCC)                                  Children and adult   Retrospective   1.5 and 3.0 T   ADC                  0 and 1000              −0.103
  Baba et al. \[[@B39]\]                 2014   Japan         79                   83                 Breast (various)                                     Adult                Retrospective   1.5 T           ADC~mean~            1000                    −0.36
  de Jong et al. \[[@B40]\]              2014   Netherlands   21                   21                 Lymphoma (DLBCL)                                     Adult                Prospective     1.5 T           ADC~mean~            0 and 1000              −0.103
  Er et al. \[[@B41]\]                   2014   Turkey        41                   41                 Rectum (adenocarcinoma)                              Adult                Retrospective   3.0 T           ADC~min~             50, 400, and 1000       −0.347
  Giganti et al. \[[@B42]\]              2014   Italy         17                   17                 Gastric (adenocarcinoma)                             Adult                Prospective     1.5 T           ADC~mean~            0 and 600               −0.01
  Grueneisen et al. \[[@B43]\]           2014   Germany       15                   54                 Cervix (various)                                     Adult                Prospective     3.0 T           ADC~min~             0, 500, and 1000        −0.342
  Iizuka et al. \[[@B44]\]               2014   Japan         15                   15                 Lung (NSCLC)                                         Adult                N               1.5 T           ADC~mean~            0, 500, and 1000        0.046
  Sakane et al. \[[@B45]\]               2015   Japan         20                   20                 Pancreas (adenocarcinoma)                            Adult                Retrospective   3.0 T           ADC~mean~            0 and 800               −0.66
  Schwenzer et al. \[[@B46]\]            2014   Germany       20                   52                 Peritoneal carcinomatosis                            Adult                Prospective     3.0 T           ADC~mean~            50 and 800              −0.58
  Sun et al. \[[@B47]\]                  2014   China         35                   35                 Cervix (various)                                     Adult                Prospective     3.0 T           ADC~mean~            0, 200, 500, and 1000   −0.505
  Yu et al. \[[@B48]\]                   2014   China         8                    34                 Peritoneal metastases                                Adult                Prospective     3.0 T           ADC~mean~            0, 400, and 800         −0.548
  Zhang et al. \[[@B49]\]                2014   China         113                  113                Lung (various)                                       Adult                N               3.0 T           ADC~mean~            1000                    −0.37
  Zukotynski et al. \[[@B50]\]           2014   USA           36                   36                 Brain (BSG)                                          Children             Retrospective   1.5 T           ADC~mean~            5 and 1000              −0.54
  Brandmaier et al. \[[@B51]\]           2015   Germany       14                   14                 Cervix (various)                                     Adult                Prospective     3.0 T           ADC~min~             0 and 800               −0.532
  Covello et al. \[[@B52]\]              2015   Italy         44                   44                 Head and neck (various)                              Adult                N               3.0 T           ADC~mean~            0, 500, and 800         −0.36
  Han et al. \[[@B53]\]                  2015   Korea         34                   34                 Head and neck (SCC)                                  Adult                Retrospective   1.5 T           ADC~min~             0 and 1000              −0.333
  Heacock et al. \[[@B54]\]              2015   USA           13                   51                 Lymphoma (various)                                   Adult                Prospective     3.0 T           ADC~mean~            0, 350, and 750         0.06
  Karan et al. \[[@B55]\]                2016   Turkey        70                   70                 Breast (IDC)                                         Adult                Retrospective   1.5 T           ADC~mean~            0, 200, 600, and 800    −0.112
  Littooij et al. \[[@B56]\]             2015   Netherlands   11                   19                 Lymphoma (various)                                   Children and adult   Prospective     1.5 T           ADC~mean~            0 and 1000              −0.24
  Liu et al. \[[@B57]\]                  2015   China         11                   11                 Lung (various)                                       Adult                N               1.5 T           ADC~mean~            1000                    −0.55
  Metz et al. \[[@B58]\]                 2015   Germany       12                   12                 Lung (metastatic NSCLC)                              Adult                Prospective     1.5 T           ADC~mean~            50, 300, and 600        0.3
  Schaarschmidt et al. \[[@B59]\]        2015   Germany       25                   100                Lymph node metastases of NSCLC                       Adult                Retrospective   3.0 T           ADC~mean~            0, 500, and 1000        −0.36

SCC: squamous cell carcinoma; NSCLC: non-small cell lung cancer; MCL: mantle cell lymphoma; DLBCL: diffuse large B cell lymphoma; HCC: hepatocellular carcinoma; BSG: brain stem glioma; IDC: invasive ductal carcinoma; N: no report.

[^1]: Academic Editor: Anne Roivainen
